Non-Accruals
The number of loans on non-accrual increased by one (1) quarter-over-quarter. As of December 31, 2022, the Company had two (2) debt investments on non-accrual with an investment cost and fair value of approximately $18.0 million and $1.7 million, respectively, or 0.6% and 0.1% as a percentage of the Company’s total investment portfolio at cost and value, respectively.
By contrast, as of September 30, 2022, the Company had one (1) debt investment on non-accrual with an investment cost and fair value of approximately $13.3 million and $0.07 million, respectively, or 0.5% and 0.0% as a percentage of the Company’s total investment portfolio at cost and value, respectively.
| | | | | | | | | | | | | | | | | | | | |
| | Q4 2022 | | | Q3 2022 | | | Q2 2022 | | | Q1 2022 | | | Q4 2021 | |
Total Investments at Cost | | $ | 3,005.7 | | | $ | 2,869.5 | | | $ | 2,763.3 | | | $ | 2,586.4 | | | $ | 2,390.9 | |
Loans on non-accrual as a % of Total Investments at Value | | | 0.1 | % | | | 0.0 | % | | | 0.1 | % | | | 0.0 | % | | | 0.4 | % |
Loans on non-accrual as a % of Total Investments at Cost | | | 0.6 | % | | | 0.5 | % | | | 0.7 | % | | | 0.5 | % | | | 1.0 | % |
Liquidity and Capital Resources
The Company ended Q4 2022 with $606.8 million in available liquidity, including $15.8 million in unrestricted cash and cash equivalents, and $591.0 million in available credit facilities, subject to existing terms, advance rates, regulatory and covenant requirements.
During Q4 2022, the Company sold 2.8 million shares of common stock under the equity ATM program for total net proceeds of approximately $39.7 million, including $0.4 million of offering expenses. As of December 31, 2022, approximately 8.5 million shares remain available for issuance and sale under the agreement.
During January 2023, the Company sold approximately 2.6 million shares of common stock under the equity ATM program for total net proceeds of approximately $34.9 million (net of $0.3 million of offering expenses).
Bank Facilities
As of December 31, 2022, there were $107.0 million outstanding borrowings under Hercules’ $545.0 million committed credit facility with MUFG as Agent and $72.0 million of outstanding borrowings under Hercules’ $225.0 million committed credit facility with SMBC.
In January 2023, Hercules expanded its borrowing capacity with a new committed letter of credit facility with SMBC of $100.0 million.
In January 2023, Hercules renewed and decreased its existing $545.0 million credit facility with MUFG to $400.0 million. The uncommitted accordion feature of $200.0 million, or a total of $600.0 million, remains the same.
Leverage
As of December 31, 2022, Hercules’ GAAP leverage ratio, including its SBA debentures, was 113.7%. Hercules’ regulatory leverage, or debt-to-equity ratio, excluding its SBA debentures, was 101.3% and net regulatory leverage, a non-GAAP measure (excluding cash of approximately $15.8 million), was 100.1%. Hercules’ net leverage ratio, including its SBA debentures, was 112.6%.
7